Cohance Lifesciences to Invest ₹23 Crore in New Hyderabad Facility.

Cohance Lifesciences is set to invest ₹23 crore (₹230 million) in a new Current Good Manufacturing Practice (cGMP) facility in Hyderabad. The new plant will focus on manufacturing oligonucleotide building blocks, a key component in emerging therapeutic treatments.

According to Vivek Sharma, Executive Chairman of Cohance Lifesciences, the investment is a strategic move to address the growing demand for cost-effective and scalable manufacturing partners. "Oligonucleotides are a fast-emerging therapeutic class, and innovators are seeking integrated, cost-efficient partners with scalable GMP capacity," Sharma said in a statement on Tuesday.

He added that the new facility will allow the company to transition high-value chemistries from laboratory-scale production to full commercial manufacturing, supporting the development of next-generation, oligonucleotide-based therapeutics.